New drug XTX301 takes on advanced cancers in first human trial
NCT ID NCT05684965
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XTX301
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early, first-in-human trial, so safety and effectiveness are not yet known. Many drug candidates fail in early testing, and benefits may be limited to certain tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HealthPartners Frauenshuh Cancer center
RECRUITINGSaint Louis Park, Minnesota, 55426, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sheboygan Cancer & Blood Specialists
WITHDRAWNSheboygan, Wisconsin, 53081, United States
-
The Gabrail Pharmacology Phase 1 Research Center
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43221, United States
Contact Email: •••••@•••••
-
Tranquil Clinical Research
COMPLETEDWebster, Texas, 77598, United States
-
University Hospital Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Email: •••••@•••••
-
University of California, Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center-Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••